- Active not recruitingPHASE1
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
This study is testing new combinations of anti-cancer medicines for people with B-cell non-Hodgkin lymphoma that has come back or not responded to previous treatments. It aims to find safe doses and see how well these new combinations work.
For: B-Cell Non-Hodgkin Lymphoma · Relapsed B-Cell Non-Hodgkin Lymphoma · Refractory B-Cell Non-Hodgkin LymphomaUnited States · Belgium · Czechia - RecruitingPHASE3
Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5
This study is testing a new combination of drugs, mosunetuzumab and lenalidomide, for follicular lymphoma. It compares this new treatment to standard chemotherapy for people who haven't had treatment before. The aim is to see if the new combination works better and is safe.
For: Follicular LymphomaAustria · Belgium · France - Active not recruitingPHASE3
A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma
This study compares two treatments for follicular lymphoma that has come back or not responded to previous treatments. It looks at a new drug, mosunetuzumab, combined with lenalidomide, versus a standard treatment, rituximab with lenalidomide, to see which works better and if they are safe.
For: Relapsed or Refractory Follicular LymphomaUnited States · Australia · Brazil - RecruitingPHASE1, PHASE2
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
This study looks at a new drug, BGB-16673, combined with other medicines for people with B-cell cancers that have come back or not responded to past treatments. It checks how safe and effective these combinations are.
For: B-cell Malignancy · Relapsed Cancer · Refractory CancerUnited States · Australia · Brazil - RecruitingPHASE1
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
This study looks at a new treatment called mosunetuzumab for chronic lymphocytic leukemia (CLL) that has come back or not responded to previous treatments. It checks how safe it is, how well it works, and how the body handles it, sometimes used with another drug, venetoclax.
For: Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaUnited States · Australia · China - RecruitingPHASE1, PHASE2
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
This study is looking into a new treatment, BMS-986458, both on its own and mixed with other anti-lymphoma medicines. It's for people in the UK with non-Hodgkin lymphoma that has come back or not responded to previous treatments. We want to see if it's safe and how well it works.
For: Relapsed/Refractory Non-Hodgkin LymphomaUnited States · Chile · China